HanchorBio is a clinical-stage biotechnology company building next-generation cancer and autoimmune therapies on its proprietary Fc-Based Designer Biologics (FBDB) platform. Founded in 2020 by Henlius co-founder Scott Liu, the company engineers multi-target Fc fusion proteins designed to reach tumors that resist conventional PD-1/PD-L1 checkpoint drugs. Its lead candidate, HCB101, is an affinity-optimized SIRPalpha-Fc fusion protein targeting the CD47-SIRPalpha 'don't eat me' pathway, engineered to spare red blood cells and avoid the anemia that sank earlier anti-CD47 programs. With operations spanning Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is advancing a pipeline across solid and hematologic cancers and autoimmune disease.
Dr. Pavan K. Cheruvu is the President and CEO of Bitterroot Bio, a Palo Alto-based biotech pioneering the field of cardio-immunology — the intersection of the immune system and cardiovascular disease. A Rhodes Scholar, board-certified cardiologist, and physician-scientist who trained at Duke, Oxford, Harvard/MIT, Johns Hopkins, and UCSF, Cheruvu is guiding Bitterroot Bio's lead program BRB-002 — a first-in-class CD47-targeting therapy for atherosclerosis — through clinical development after a landmark $145M Series A in 2023 and positive Phase 1 results in 2025.